OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 217,900 shares, a decrease of 35.5% from the February 28th total of 338,000 shares. Based on an average daily volume of 178,700 shares, the short-interest ratio is currently 1.2 days. Currently, 0.9% of the shares of the stock are sold short.
OKYO Pharma Stock Down 5.6 %
NASDAQ OKYO traded down $0.08 during mid-day trading on Friday, hitting $1.35. The stock had a trading volume of 44,082 shares, compared to its average volume of 114,402. The firm’s 50 day moving average is $1.21 and its 200 day moving average is $1.12. OKYO Pharma has a twelve month low of $0.81 and a twelve month high of $1.74.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Tuesday, February 18th.
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
See Also
- Five stocks we like better than OKYO Pharma
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 03/24 – 03/28
- Bank Stocks – Best Bank Stocks to Invest In
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
